только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 4 / 10
Страница 1 / 1

Список литературы

  1. WHO Classification of Skin Tumours, 4th edn; 2018.
  2. Verkouteren JAC, Ramdas KHR, Wakkee M, Nijsten T: Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol 2017, 177(2):359-372.
  3. Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988, 124(6):869-871.
  4. Rosso S, Zanetti R, Martinez C, Tormo MJ, Schraub S, Sancho-Garnier H, Franceschi S, Gafa L, Perea E, Navarro C et al: The multicentre south European study "Helios". II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996, 73(11):1447-1454.
  5. Gupta AK, Cardella CJ, Haberman HF: Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol 1986, 122(11):1288-1293.
  6. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, Fauchald P, Simonsen S: Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999, 40(2 Pt 1):177-186.
  7. Patel RV, Clark LN, Lebwohl M, Weinberg JM: Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009, 60(6):1001-1017.
  8. Silverberg MJ, Leyden W, Warton EM, Quesenberry CP, Jr., Engels EA, Asgari MM: HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst 2013, 105(5):350-360.
  9. Asgari MM, Arron ST, Warton EM, Quesenberry CP, Jr., Weisshaar D: Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs). J Am Acad Dermatol 2015, 73(3):444-450.
  10. Brewer JD, Shanafelt TD, Khezri F, Sosa Seda IM, Zubair AS, Baum CL, Arpey CJ, Cerhan JR, Call TG, Roenigk RK et al: Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in Minnesota. J Am Acad Dermatol 2015, 72(2):302-309.
  11. Gerber SR, Seifert B, Inci I, Serra AL, Kohler M, Benden C, Hofbauer GF, Schuurmans MM: Exposure to moxifloxacin and cytomegalovirus replication is associated with skin squamous cell carcinoma development in lung transplant recipients. J Eur Acad Dermatol Venereol 2015, 29(12):2451-2457.
  12. Hock BD, McIntosh ND, McKenzie JL, Pearson JF, Simcock JW, MacPherson SA: Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients. Intern Med J 2016, 46(12):1414-1421.
  13. van den Heuvel TR, Wintjens DS, Jeuring SF, Wassink MH, Romberg-Camps MJ, Oostenbrug LE, Sanduleanu S, Hameeteman WH, Zeegers MP, Masclee AA et al: Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer 2016, 139(6):1270-1280.
  14. Diffey BL, Norval M, Albers PN, Wright CY: The influence of HIV infection on the age dependence of squamous cell carcinoma of the skin in South Africa. S Afr Med J 2017, 107(2):127-129.
  15. Zilinska Z, Sersenova M, Chrastina M, Breza J, Sr., Bena L, Baltesova T, Jurcina A, Roland R, Lackova E, Cellar M et al: Occurrence of malignancies after kidney transplantation in adults: Slovak multicenter experience. Neoplasma 2017, 64(2):311-317.
  16. Stern RS, Lunder EJ: Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998, 134(12):1582-1585.
  17. Leffell DJ, Carucci JA: Management of Skin Cancer. In: Cancer: Principles and Practice of Oncology. 6th edn. Edited by Devita VT, Hellman S, Rosenberg SA: Lippincott Williams & Wilkins; .
  18. Edwards MJ, Hirsch RM, Broadwater JR, Netscher DT, Ames FC: Squamous cell carcinoma arising in previously burned or irradiated skin. Arch Surg 1989, 124(1):115-117.
  19. Rowe DE, Carroll RJ, Day CL, Jr.: Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992, 26(6):976-990.
  20. Eroglu A, Berberoglu U, Berreroglu S: Risk factors related to locoregional recurrence in squamous cell carcinoma of the skin. J Surg Oncol 1996, 61(2):124-130.
  21. Snyder RJ, Stillman RM, Weiss SD: Epidermoid cancers that masquerade as venous ulcer disease. Ostomy Wound Manage 2003, 49(4):63-64, 65-66.
  22. Combemale P, Bousquet M, Kanitakis J, Bernard P, Angiodermatology Group FSoD: Malignant transformation of leg ulcers: a retrospective study of 85 cases. J Eur Acad Dermatol Venereol 2007, 21(7):935-941.
  23. Al-Zacko SM: Malignancy in chronic burn scar: a 20 year experience in Mosul-Iraq. Burns 2013, 39(7):1488-1491.
  24. Karasoy Yesilada A, Zeynep Sevim K, Ozgur Sucu D, Akcal A, Karsidag S, Kilinc L, Orhan Kizilkaya H: Marjolin ulcer: clinical experience with 34 patients over 15 years. J Cutan Med Surg 2013, 17(6):404-409.
  25. Natafji N, Tidman MJ: Improving detection of non-melanoma skin cancer Non- melanoma skin cancer. Practitioner 2015, 259(1784):23-27, 23.
  26. Onesti MG, Fino P, Fioramonti P, Amorosi V, Scuderi N: Ten years of experience in chronic ulcers and malignant transformation. Int Wound J 2015, 12(4):447-450.
  27. Khullar G, Saikia UN, De D, Handa S, Das Radotra B: Predisposing factors and histopathological variants of cutaneous squamous cell carcinoma: Experience from a North Indian teaching hospital. Indian J Dermatol Venereol Leprol 2016, 82(3):273-278.
  28. Marks R, Rennie G, Selwood TS: Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988, 1(8589):795-797.
  29. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF, Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial G: Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009, 115(11):2523-2530.
  30. Eimpunth S, Goldenberg A, Hamman MS, Oganesyan G, Lee RA, Hunnangkul S, Song SS, Greywal T, Jiang SIB: Squamous Cell Carcinoma In Situ Upstaged to Invasive Squamous Cell Carcinoma: A 5-Year, Single Institution Retrospective Review. Dermatol Surg 2017, 43(5):698- 703.
  31. Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS: Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol 2014, 134(1):213-220.
  32. Luande J, Henschke CI, Mohammed N: The Tanzanian human albino skin. Natural history. Cancer 1985, 55(8):1823-1828.
  33. Kraemer KH, Lee MM, Scotto J: Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987, 123(2):241-250.
  34. Bradford PT, Goldstein AM, Tamura D, Khan SG, Ueda T, Boyle J, Oh KS, Imoto K, Inui H, Moriwaki S et al: Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet 2011, 48(3):168-176.
  35. Mabula JB, Chalya PL, McHembe MD, Jaka H, Giiti G, Rambau P, Masalu N, Kamugisha E, Robert S, Gilyoma JM: Skin cancers among Albinos at a University teaching hospital in Northwestern Tanzania: a retrospective review of 64 cases. BMC Dermatol 2012, 12:5.
  36. Halkud R, Shenoy AM, Naik SM, Chavan P, Sidappa KT, Biswas S: Xeroderma pigmentosum: clinicopathological review of the multiple oculocutaneous malignancies and complications. Indian J Surg Oncol 2014, 5(2):120-124.
  37. Gandini S, Palli D, Spadola G, Bendinelli B, Cocorocchio E, Stanganelli I, Miligi L, Masala G, Caini S: Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol 2018, 122:1-9.
  38. Chen P, Chen F, Zhou B: Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma. Clin Exp Dermatol 2019, 44(3):243-251.
  39. Tang H, Fu S, Zhai S, Song Y, Asgari MM, Han J: Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2018, 27(3):279-288.
  40. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, Coldiron BM: Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010, 146(3):283-287.
  41. Lomas A, Leonardi-Bee J, Bath-Hextall F: A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012, 166(5):1069-1080.
  42. Rubin AI, Chen EH, Ratner D: Basal-cell carcinoma. N Engl J Med 2005, 353(21):2262- 2269.
  43. Kuo KY, Batra P, Cho HG, Li S, Chahal HS, Rieger KE, Tang JY, Sarin KY: Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution. J Am Acad Dermatol 2017, 77(2):233-234 e232.
  44. Каприн АД, Старинский ВВ, Петрова ГВ (eds.): Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018.
  45. Каприн АД, Старинский ВВ, Петрова ГВ (eds.): Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019.
  46. International Statistical Classification of Diseases and Related Health Problems 10th Revision [http://apps.who.int/classifications/icd10/browse/2016/en]
  47. Brierley JD, Gospodarowicz MK, Wittekind C (eds.): TNM classification of malignant tumors, 8th edn. Oxford, UK: John Wiley & Sons, Inc; 2017.
  48. Shmults CD, Blitzblau R, Aasi SA, Alam M, Andersen JS, Bordeaux J, Bowen GM, Carson W, Chen P-L, Contreras CM et al: NCCN Guidelienes Version 1.2020. Squamous Cell Skin Cancer. In.: NCCN; 2019.
  49. Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL: Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis. JAMA Dermatol 2016, 152(4):419-428.
  50. Swanson NA: Mohs surgery. Technique, indications, applications, and the future. Arch Dermatol 1983, 119(9):761-773.
  51. Prieto-Granada C, Rodriguez-Waitkus P: Cutaneous squamous cell carcinoma and related entities: Epidemiology, clinical and histological features, and basic science overview. Curr Probl Cancer 2015, 39(4):206-215.
  52. Burton KA, Ashack KA, Khachemoune A: Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease. Am J Clin Dermatol 2016, 17(5):491-508.
  53. Kwiek B, Schwartz RA: Keratoacanthoma (KA): An update and review. J Am Acad Dermatol 2016, 74(6):1220-1233.
  54. Oshyvalova OO, Kaliuzhna LD, Kropelnytskyi VO: Clinical forms of actinic keratosis and levels of dysplasia of the epidermis. Wiad Lek 2017, 70(6 pt 1):1072-1078.
  55. Parekh V, Seykora JT: Cutaneous Squamous Cell Carcinoma. Clin Lab Med 2017, 37(3):503-525.
  56. Que SKT, Zwald FO, Schmults CD: Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol 2018, 78(2):237-247.
  57. deShazo R, Soltani-Arabshahi R, Krishnasamy S, Langley RG, Kalia S, Stahle M, Langholff W, Goyal K, Fakharzadeh S, Galindo C et al: Non-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol 2019, 18(10):1059-1060.
  58. Elnahas S, Olson MT, Kang P, Panchanathan R, Masuda T, Walia R, Zeitouni NC, Smith MA, Bremner RM: Factors associated with skin cancer in lung transplant recipients: A single- center experience. Clin Transplant 2019:e13718.
  59. Huang JT, Coughlin CC, Hawryluk EB, Hook K, Humphrey SR, Kruse L, Lawley L, Al-Sayegh H, London WB, Marghoob A et al: Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults. J Pediatr 2019, 211:152-158.
  60. Oliveira WRP, Tirico M, Souza AAV, Codarin FR, Silva LLC, Festa Neto C: Skin lesions in organ transplant recipients: a study of 177 consecutive Brazilian patients. Int J Dermatol 2019, 58(4):440-448.
  61. Oh CC, Lee HY, Tan BK, Assam PN, Kee TYS, Pang SM: Dermatological conditions seen in renal transplant recipients in a Singapore tertiary hospital. Singapore Med J 2018, 59(10):519-523.
  62. Collins L, Quinn A, Stasko T: Skin Cancer and Immunosuppression. Dermatol Clin 2019, 37(1):83-94.
  63. Lee CT, Lehrer EJ, Aphale A, Lango M, Galloway TJ, Zaorsky NG: Surgical excision, Mohs micrographic surgery, external-beam radiotherapy, or brachytherapy for indolent skin cancer: An international meta-analysis of 58 studies with 21,000 patients. Cancer 2019, 125(20):3582-3594.
  64. Dinnes J, Deeks JJ, Chuchu N, Matin RN, Wong KY, Aldridge RB, Durack A, Gulati A, Chan SA, Johnston L et al: Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults. Cochrane Database Syst Rev 2018, 12:CD011901.
  65. Dinnes J, Deeks JJ, Grainge MJ, Chuchu N, Ferrante di Ruffano L, Matin RN, Thomson DR, Wong KY, Aldridge RB, Abbott R et al: Visual inspection for diagnosing cutaneous melanoma in adults. Cochrane Database of Systematic Reviews 2018(12).
  66. Grange F: [Multiple primary melanoma and familial melanoma. Risk evaluation and screening tests. How to evaluate the risk of developing a second melanoma? In what family? Should screening methods be implemented? Which ones and why?]. Ann Dermatol Venereol 1995, 122(5):365-371.
  67. Claeson M, Holmstrom P, Hallberg S, Gillstedt M, Gonzalez H, Wennberg AM, Paoli J: Multiple Primary Melanomas: A Common Occurrence in Western Sweden. Acta Derm Venereol 2016.
  68. Moore MM, Geller AC, Warton EM, Schwalbe J, Asgari MM: Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011. J Am Acad Dermatol 2015, 73(4):630-636.
  69. Force USPST, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Ebell M, Epling JW, Jr., Garcia FA, Gillman MW, Kemper AR et al: Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2016, 316(4):429-435.
  70. Lallas A, Argenziano G, Zendri E, Moscarella E, Longo C, Grenzi L, Pellacani G, Zalaudek I: Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring. Expert Rev Anticancer Ther 2013, 13(5):541-558.
  71. Wernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Blasi PR: Screening for Skin Cancer in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016, 316(4):436-447.
  72. Lallas A, Pyne J, Kyrgidis A, Andreani S, Argenziano G, Cavaller A, Giacomel J, Longo C, Malvestiti A, Moscarella E et al: The clinical and dermoscopic features of invasive cutaneous squamous cell carcinoma depend on the histopathological grade of differentiation. Br J Dermatol 2015, 172(5):1308-1315.
  73. Manfredini M, Longo C, Ferrari B, Piana S, Benati E, Casari A, Pellacani G, Moscarella E: Dermoscopic and reflectance confocal microscopy features of cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol 2017, 31(11):1828-1833.
  74. Weber P, Tschandl P, Sinz C, Kittler H: Dermatoscopy of Neoplastic Skin Lesions: Recent Advances, Updates, and Revisions. Curr Treat Options Oncol 2018, 19(11):56.
  75. Payapvipapong K, Tanaka M: Dermoscopic classification of Bowen"s disease. Australas J Dermatol 2015, 56(1):32-35.
  76. Ferrante di Ruffano L, Dinnes J, Chuchu N, Bayliss SE, Takwoingi Y, Davenport C, Matin RN, O"Sullivan C, Roskell D, Deeks JJ et al: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults. Cochrane Database Syst Rev 2018, 12:CD013187.
  77. Бровкина АФ: Офтальмоонкология. Москва: Медицина; 2002.
  78. Бровкина АФ, Панова ИЕ, Саакян СВ: Офтальмоонкология: новое за последние два десятилетия. Вестник офтальмологии 2014, 130(6):13-19.
  79. Вальский ВВ, Бородин ЮИ, Саакян СВ: Эффективность протонотерапии эпителиальных злокачественных опухолей придаточного аппарата глаза редуцированной суммарной очаговой дозой. Опухоли головы и шеи 2016, 1(6):47-48.
  80. Важенина ДА, Васильев СА, Дудник СН: Рецидивирующий базальноклеточный рак кожи век (особенности клинического течения, лечения). Российский медицинский журнал 2016, 11:36-43.
  81. Енгибарян МА, Пустовая ИВ, Ульянова ЮВ: Первичная аутопластика в хирургическом лечении опухолей внутреннего угла глаза. Известия ВУЗ Северо- Кавказский Регион Естественные Науки 2011:34-36.
  82. Панова ИЕ, Васильев СА, Семенов ЛЕ: Рецидивирующий базальноклеточный рак кожи век. Клиническая офтальмология 2006, 7(1):11-14.
  83. Walsh MF, Chang VY, Kohlmann WK, Scott HS, Cunniff C, Bourdeaut F, Molenaar JJ, Porter CC, Sandlund JT, Plon SE et al: Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders. Clin Cancer Res 2017, 23(11):e23-e31.
  84. Tofuku Y, Nobeyama Y, Kamide R, Moriwaki S, Nakagawa H: Xeroderma pigmentosum complementation group F: Report of a case and review of Japanese patients. J Dermatol 2015, 42(9):897-899.
  85. Pace P: [Eugenic consultation]. Minerva Med 1974, 65(90):4754-4760.
  86. Kraemer KH, DiGiovanna JJ: Xeroderma Pigmentosum. In: GeneReviews((R)). edn. Edited by Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A. Seattle (WA); 1993.
  87. Naik SM, Shenoy AM, Nanjundappa A, Halkud R, Chavan P, Sidappa K, Gupta S: Cutaneous malignancies in xeroderma pigmentosum: earlier management improves survival. Indian J Otolaryngol Head Neck Surg 2013, 65(2):162-167.
  88. Christen-Zaech S, Imoto K, Khan SG, Oh KS, Tamura D, Digiovanna JJ, Boyle J, Patronas NJ, Schiffmann R, Kraemer KH et al: Unexpected occurrence of xeroderma pigmentosum in an uncle and nephew. Arch Dermatol 2009, 145(11):1285-1291.
  89. Poblete-Gutierrez P, Burgdorf WH, Has C, Berneburg M, Frank J: [Hereditary photodermatoses]. Hautarzt 2006, 57(12):1067-1082.
  90. Maeda T, Sato K, Minami H, Taguchi H, Yoshikawa K: PCR-RFLP analysis as an aid to genetic counseling of families of Japanese patients with group A xeroderma pigmentosum. J Invest Dermatol 1997, 109(3):306-309.
  91. Yang Y, Ding B, Wang K, Bu D, Tu P, Zhu X: DNA-based prenatal diagnosis in a Chinese family with xeroderma pigmentosum group A. Br J Dermatol 2004, 150(6):1190-1193.
  92. Itin PH, Fistarol SK: [Genetic counseling and DNA testing in patients with increased risks for malignant melanoma]. Ther Umsch 2003, 60(8):469-472.
  93. Oda T, Sue M, Sasaki Y, Ogura I: Diffusion-weighted magnetic resonance imaging in oral and maxillofacial lesions: preliminary study on diagnostic ability of apparent diffusion coefficient maps. Oral Radiol 2018, 34(3):224-228.
  94. Mendenhall WM, Ferlito A, Takes RP, Bradford CR, Corry J, Fagan JJ, Rinaldo A, Strojan P, Rodrigo JP: Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. Oral Oncol 2012, 48(10):918-922.
  95. Balamucki CJ, DeJesus R, Galloway TJ, Mancuso AA, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM: Impact of radiographic findings on for prognosis skin cancer with perineural invasion. Am J Clin Oncol 2015, 38(3):248-251.
  96. Newlands C, Currie R, Memon A, Whitaker S, Woolford T: Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016, 130(S2):S125- S132.
  97. Marrazzo G, Thorpe R, Condie D, Pinho MC, Srivastava D: Clinical and Pathologic Factors Predictive of Positive Radiologic Findings in High-Risk Cutaneous Squamous Cell Carcinoma. Dermatol Surg 2015, 41(12):1405-1410.
  98. Ruiz ES, Karia PS, Morgan FC, Schmults CD: The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management. J Am Acad Dermatol 2017, 76(2):217-225.
  99. Gandhi MR, Panizza B, Kennedy D: Detecting and defining the anatomic extent of large nerve perineural spread of malignancy: comparing "targeted" MRI with the histologic findings following surgery. Head Neck 2011, 33(4):469-475.
  100. Williams LS, Mancuso AA, Mendenhall WM: Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis. Int J Radiat Oncol Biol Phys 2001, 49(4):1061-1069.
  101. Nemzek WR, Hecht S, Gandour-Edwards R, Donald P, McKennan K: Perineural spread of head and neck tumors: how accurate is MR imaging? AJNR Am J Neuroradiol 1998, 19(4):701- 706.
  102. Buchwald HJ, Muller A, Kampmeier J, Lang GK: [Optical coherence tomography versus ultrasound biomicroscopy of conjunctival and eyelid lesions]. Klin Monbl Augenheilkd 2003, 220(12):822-829.
  103. Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S et al: MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology 2018, 19(7):916-929.
  104. Bichakjian C, Aasi SZ, Alam M, Andersen JS, Blitzblau R, Bordeaux J, Bowen GM, Chen PL, Contreras CM, Mackenzie D et al: Basal cell skin cancer. NCCN clinical practice guidelines in oncology. Version 1.2019 - August 31.2018. 2019:46.
  105. Brodland DG, Zitelli JA: Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992, 27(2 Pt 1):241-248.
  106. Baker NJ, Webb AA, Macpherson D: Surgical management of cutaneous squamous cell carcinoma of the head and neck. Br J Oral Maxillofac Surg 2001, 39(2):87-90.
  107. Griffiths RW, Feeley K, Suvarna SK: Audit of clinical and histological prognostic factors in primary invasive squamous cell carcinoma of the skin: assessment in a minimum 5 year follow-up study after conventional excisional surgery. Br J Plast Surg 2002, 55(4):287- 292.
  108. Ang P, Tan AW, Goh CL: Comparison of completely versus incompletely excised cutaneous squamous cell carcinomas. Ann Acad Med Singapore 2004, 33(1):68-70.
  109. Nemet AY, Deckel Y, Martin PA, Kourt G, Chilov M, Sharma V, Benger R: Management of periocular basal and squamous cell carcinoma: a series of 485 cases. Am J Ophthalmol 2006, 142(2):293-297.
  110. Mourouzis C, Boynton A, Grant J, Umar T, Wilson A, Macpheson D, Pratt C: Cutaneous head and neck SCCs and risk of nodal metastasis - UK experience. J Craniomaxillofac Surg 2009, 37(8):443-447.
  111. Seretis K, Thomaidis V, Karpouzis A, Tamiolakis D, Tsamis I: Epidemiology of surgical treatment of nonmelanoma skin cancer of the head and neck in Greece. Dermatol Surg 2010, 36(1):15-22.
  112. van der Eerden PA, Prins ME, Lohuis PJ, Balm FA, Vuyk HD: Eighteen years of experience in Mohs micrographic surgery and conventional excision for nonmelanoma skin cancer treated by a single facial plastic surgeon and pathologist. Laryngoscope 2010, 120(12):2378-2384.
  113. Maciburko SJ, Townley WA, Hollowood K, Giele HP: Skin cancers of the hand: a series of 541 malignancies. Plast Reconstr Surg 2012, 129(6):1329-1336.
  114. Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ: Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2013, 133(5):1188-1196.
  115. Schell AE, Russell MA, Park SS: Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery. JAMA Facial Plast Surg 2013, 15(5):337-343.
  116. Jenkins G, Smith AB, Kanatas AN, Houghton DR, Telfer MR: Anatomical restrictions in the surgical excision of scalp squamous cell carcinomas: does this affect local recurrence and regional nodal metastases? Int J Oral Maxillofac Surg 2014, 43(2):142-146.
  117. Brinkman JN, Hajder E, van der Holt B, Den Bakker MA, Hovius SE, Mureau MA: The Effect of Differentiation Grade of Cutaneous Squamous Cell Carcinoma on Excision Margins, Local Recurrence, Metastasis, and Patient Survival: A Retrospective Follow-Up Study. Ann Plast Surg 2015, 75(3):323-326.
  118. Pugliano-Mauro M, Goldman G: Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma. Dermatol Surg 2010, 36(10):1544-1553.
  119. Batra RS, Kelley LC: Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery. Arch Dermatol 2002, 138(8):1043-1051.
  120. Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R: Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005, 53(2):253-260.
  121. Bogdanov-Berezovsky A, Cohen AD, Glesinger R, Cagnano E, Rosenberg L: Risk factors for incomplete excision of squamous cell carcinomas. J Dermatolog Treat 2005, 16(5-6):341- 344.
  122. Khan AA, Potter M, Cubitt JJ, Khoda BJ, Smith J, Wright EH, Scerri G, Crick A, Cassell OC, Budny PG: Guidelines for the excision of cutaneous squamous cell cancers in the United Kingdom: the best cut is the deepest. J Plast Reconstr Aesthet Surg 2013, 66(4):467-471.
  123. Fraunfelder FT, Zacarian SA, Limmer BL, Wingfield D: Cryosurgery for malignancies of the eyelid. Ophthalmology 1980, 87(6):461-465.
  124. Zacarian SA: Cryosurgery of cutaneous carcinomas. An 18-year study of 3,022 patients with 4,228 carcinomas. J Am Acad Dermatol 1983, 9(6):947-956.
  125. Holt PJ: Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br J Dermatol 1988, 119(2):231-240.
  126. Kuflik EG, Gage AA: The five-year cure rate achieved by cryosurgery for skin cancer. J Am Acad Dermatol 1991, 24(6 Pt 1):1002-1004.
  127. Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM: Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen"s disease. Br J Dermatol 1996, 135(5):766-771.
  128. Ahmed I, Berth-Jones J, Charles-Holmes S, O"Callaghan CJ, Ilchyshyn A: Comparison of cryotherapy with curettage in the treatment of Bowen"s disease: a prospective study. Br J Dermatol 2000, 143(4):759-766.
  129. Morton CA, Whitehurst C, Moore JV, MacKie RM: Comparison of red and green light in the treatment of Bowen"s disease by photodynamic therapy. Br J Dermatol 2000, 143(4):767- 772.
  130. Morton CA, Whitehurst C, McColl JH, Moore JV, MacKie RM: Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001, 137(3):319-324.
  131. Salim A, Leman JA, McColl JH, Chapman R, Morton CA: Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen"s disease. Br J Dermatol 2003, 148(3):539-543.
  132. Morton C, Horn M, Leman J, Tack B, Bedane C, Tjioe M, Ibbotson S, Khemis A, Wolf P: Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol 2006, 142(6):729-735.
  133. Patel GK, Goodwin R, Chawla M, Laidler P, Price PE, Finlay AY, Motley RJ: Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen"s disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006, 54(6):1025- 1032.
  134. Peris K, Micantonio T, Fargnoli MC, Lozzi GP, Chimenti S: Imiquimod 5% cream in the treatment of Bowen"s disease and invasive squamous cell carcinoma. J Am Acad Dermatol 2006, 55(2):324-327.
  135. Hansen JP, Drake AL, Walling HW: Bowen"s Disease: a four-year retrospective review of epidemiology and treatment at a university center. Dermatol Surg 2008, 34(7):878-883.
  136. Warshauer E, Warshauer BL: Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy. J Drugs Dermatol 2008, 7(5):447-451.
  137. Lindemalm-Lundstam B, Dalenback J: Prospective follow-up after curettage- cryosurgery for scalp and face skin cancers. Br J Dermatol 2009, 161(3):568-576.
  138. Love WE, Bernhard JD, Bordeaux JS: Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009, 145(12):1431- 1438.
  139. Peikert JM: Prospective trial of curettage and cryosurgery in the management of non-facial, superficial, and minimally invasive basal and squamous cell carcinoma. Int J Dermatol 2011, 50(9):1135-1138.
  140. Overmark M, Koskenmies S, Pitkanen S: A Retrospective Study of Treatment of Squamous Cell Carcinoma In situ. Acta Derm Venereol 2016, 96(1):64-67.
  141. Varma S, Wilson H, Kurwa HA, Gambles B, Charman C, Pearse AD, Taylor D, Anstey AV: Bowen"s disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol 2001, 144(3):567-574.
  142. Lui H, Hobbs L, Tope WD, Lee PK, Elmets C, Provost N, Chan A, Neyndorff H, Su XY, Jain H et al: Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol 2004, 140(1):26-32.
  143. Haddad R, Nesher E, Weiss J, Skornick Y, Kashtan H: Photodynamic therapy for Bowen"s disease and squamous cell carcinoma of the skin. Photodiagnosis Photodyn Ther 2004, 1(3):225-230.
  144. Calzavara-Pinton PG, Venturini M, Sala R, Capezzera R, Parrinello G, Specchia C, Zane C: Methylaminolaevulinate-based photodynamic therapy of Bowen"s disease and squamous cell carcinoma. Br J Dermatol 2008, 159(1):137-144.
  145. Ko DY, Kim KH, Song KH: A randomized trial comparing methyl aminolaevulinate photodynamic therapy with and without Er:YAG ablative fractional laser treatment in Asian patients with lower extremity Bowen disease: results from a 12-month follow-up. Br J Dermatol 2014, 170(1):165-172.
  146. Bath-Hextall FJ, Matin RN, Wilkinson D, Leonardi-Bee J: Interventions for cutaneous Bowen"s disease. The Cochrane database of systematic reviews 2013(6):CD007281.
  147. Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J: Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 2013, 347:f6153.
  148. Honeycutt WM, Jansen GT: Treatment of squamous cell carcinoma of the skin. Arch Dermatol 1973, 108(5):670-672.
  149. Shiffman NJ: Squamous cell carcinomas of the skin of the pinna. Can J Surg 1975, 18(3):279-283.
  150. Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP: Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope 2009, 119(10):1994-1999.
  151. Hernandez-Machin B, Borrego L, Gil-Garcia M, Hernandez BH: Office-based radiation therapy for cutaneous carcinoma: evaluation of 710 treatments. Int J Dermatol 2007, 46(5):453-459.
  152. Veness MJ, Delishaj D, Barnes EA, Bezugly A, Rembielak A: Current Role of Radiotherapy in Non-melanoma Skin Cancer. Clin Oncol (R Coll Radiol) 2019, 31(11):749-758.
  153. Grossi Marconi D, da Costa Resende B, Rauber E, de Cassia Soares P, Fernandes JMJ, Mehta N, Lopes Carvalho A, Kupelian PA, Chen A: Head and Neck Non-Melanoma Skin Cancer Treated By Superficial X-Ray Therapy: An Analysis of 1021 Cases. PLoS One 2016, 11(7):e0156544.
  154. Tsao MN, Tsang RW, Liu FF, Panzarella T, Rotstein L: Radiotherapy management for squamous cell carcinoma of the nasal skin: the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 2002, 52(4):973-979.
  155. Abbatucci JS, Boulier N, Laforge T, Lozier JC: Radiation therapy of skin carcinomas: results of a hypofractionated irradiation schedule in 675 cases followed more than 2 years. Radiother Oncol 1989, 14(2):113-119.
  156. van Hezewijk M, Creutzberg CL, Putter H, Chin A, Schneider I, Hoogeveen M, Willemze R, Marijnen CA: Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases. Radiother Oncol 2010, 95(2):245-249.
  157. Clark C, Bryden A, Dawe R, Moseley H, Ferguson J, Ibbotson SH: Topical 5- aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed 2003, 19(3):134-141.
  158. Церковский ДА, Мазуренко АН, Петровская НА, Артемьева ТП: Фотодинамическая терапия базальноклеточного рака кожи с фотосенсибилизатором фотолон. Biomedical Photonics 2017, 6(1):12-19.
  159. Chan AL, Juarez M, Allen R, Volz W, Albertson T: Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces. Photodermatol Photoimmunol Photomed 2005, 21(2):72-78.
  160. Kochneva EV, Filonenko EV, Vakulovskaya EG, Scherbakova EG, Seliverstov OV, Markichev NA, Reshetnickov AV: Photosensitizer Radachlorin(R): Skin cancer PDT phase II clinical trials. Photodiagnosis Photodyn Ther 2010, 7(4):258-267.
  161. Rosen T, Harting M, Gibson M: Treatment of Bowen"s disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg 2007, 33(4):427-431; discussion 431-422.
  162. Ross AS, Schmults CD: Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg 2006, 32(11):1309- 1321.
  163. Renzi C, Caggiati A, Mannooranparampil TJ, Passarelli F, Tartaglione G, Pennasilico GM, Cecconi S, Potenza C, Pasquini P: Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature. Eur J Surg Oncol 2007, 33(3):364-369.
  164. Ahmed MM, Moore BA, Schmalbach CE: Utility of head and neck cutaneous squamous cell carcinoma sentinel node biopsy: a systematic review. Otolaryngol Head Neck Surg 2014, 150(2):180-187.
  165. Fukushima S, Masuguchi S, Igata T, Harada M, Aoi J, Miyashita A, Nakahara S, Inoue Y, Jinnin M, Shiraishi S et al: Evaluation of sentinel node biopsy for cutaneous squamous cell carcinoma. J Dermatol 2014, 41(6):539-541.
  166. Schmitt AR, Brewer JD, Bordeaux JS, Baum CL: Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol 2014, 150(1):19-24.
  167. Takahashi A, Imafuku S, Nakayama J, Nakaura J, Ito K, Shibayama Y: Sentinel node biopsy for high-risk cutaneous squamous cell carcinoma. Eur J Surg Oncol 2014, 40(10):1256- 1262.
  168. Allen JE, Stolle LB: Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinoma. Eur J Surg Oncol 2015, 41(2):197-200.
  169. Krediet JT, Beyer M, Lenz K, Ulrich C, Lange-Asschenfeldt B, Stockfleth E, Terhorst D: Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma. Br J Dermatol 2015, 172(4):1029-1036.
  170. Durham AB, Lowe L, Malloy KM, McHugh JB, Bradford CR, Chubb H, Johnson TM, McLean SA: Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma on the Head and Neck. JAMA Otolaryngol Head Neck Surg 2016, 142(12):1171-1176.
  171. Gore SM, Shaw D, Martin RC, Kelder W, Roth K, Uren R, Gao K, Davies S, Ashford BG, Ngo Q et al: Prospective study of sentinel node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 2016, 38 Suppl 1:E884-889.
  172. Maruyama H, Tanaka R, Fujisawa Y, Nakamura Y, Ito S, Fujimoto M: Availability of sentinel lymph node biopsy for cutaneous squamous cell carcinoma. J Dermatol 2017, 44(4):431-437.
  173. Hauschild A, Breuninger H, Kaufmann R, Kortmann RD, Klein M, Werner J, Reifenberger J, Dirschka T, Garbe C: Brief S2k guidelines--Basal cell carcinoma of the skin. J Dtsch Dermatol Ges 2013, 11 Suppl 3:10-15, 11-16.
  174. Rowe DE, Carroll RJ, Day CL, Jr.: Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989, 15(4):424-431.
  175. Rowe DE, Carroll RJ, Day CL, Jr.: Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989, 15(3):315-328.
  176. Petit JY, Avril MF, Margulis A, Chassagne D, Gerbaulet A, Duvillard P, Auperin A, Rietjens M: Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg 2000, 105(7):2544-2551.
  177. Avril MF, Auperin A, Margulis A, Gerbaulet A, Duvillard P, Benhamou E, Guillaume JC, Chalon R, Petit JY, Sancho-Garnier H et al: Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 1997, 76(1):100-106.
  178. Dundar Y, Cannon RB, Hunt JP, Monroe M, Suneja G, Hitchcock YJ: Radiotherapy regimens in patients with nonmelanoma head and neck skin cancers. Int J Dermatol 2018, 57(4):441-448.
  179. Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD: Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg 2009, 35(4):574-585.
  180. Veness MJ, Morgan GJ, Palme CE, Gebski V: Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 2005, 115(5):870-875.
  181. Wray J, Amdur RJ, Morris CG, Werning J, Mendenhall WM: Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp. Radiat Oncol 2015, 10:199.
  182. Тимофеев ЛВ, Саакян СВ, Волошин СВ, Архипов АЮ: Аппликаторы для офтальмоонкологии. Стронций-90 + Иттрий-90. Москва; 2019.
  183. Chopdar A: Carbon-dioxide laser treatment of eye lid lesions. Trans Ophthalmol Soc U K 1985, 104 ( Pt 2):176-180.
  184. Вальский ВВ: Крупнофракционная брахитерапия злокачественных опухолей конъюнктивы. In: Достижения и перспективы офтальмоонкологии. edn. Москва; 2001: 98- 100.
  185. Бровкина АФ: Лучевая терапия в лечении опухолей органа зрения. Клин офтальмология 2003, 4(1):15-19.
  186. Тимофеев ЛВ: Физические, технические, некоторые радиобиологические и медицинские аспекты контактной лучевой (бета ̶ ) терапии. . Москва; 2016.
  187. Тимофеев ЛВ: Расчетные методы дозиметрии бета-излучения. Москва: Типография "Вашформат",; 2017.
  188. Laskar S, Gurram L, Laskar SG, Chaudhari S, Khanna N, Upreti R: Superficial ocular malignancies treated with strontium-90 brachytherapy: long term outcomes. J Contemp Brachytherapy 2015, 7(5):369-373.
  189. Lecuona K, Stannard C, Hart G, Rice J, Cook C, Wetter J, Duffield M: The treatment of carcinoma in situ and squamous cell carcinoma of the conjunctiva with fractionated strontium-90 radiation in a population with a high prevalence of HIV. Br J Ophthalmol 2015, 99(9):1158-1161.
  190. Stannard C, Sauerwein W, Maree G, Lecuona K: Radiotherapy for ocular tumours. Eye (Lond) 2013, 27(2):119-127.
  191. Veness MJ, Palme CE, Smith M, Cakir B, Morgan GJ, Kalnins I: Cutaneous head and neck squamous cell carcinoma metastatic to cervical lymph nodes (nonparotid): a better outcome with surgery and adjuvant radiotherapy. Laryngoscope 2003, 113(10):1827-1833.
  192. Hinerman RW, Indelicato DJ, Amdur RJ, Morris CG, Werning JW, Vaysberg M, Kirwan J, Mendenhall WM: Cutaneous squamous cell carcinoma metastatic to parotid-area lymph nodes. Laryngoscope 2008, 118(11):1989-1996.
  193. Jol JA, van Velthuysen ML, Hilgers FJ, Keus RB, Neering H, Balm AJ: Treatment results of regional metastasis from cutaneous head and neck squamous cell carcinoma. Eur J Surg Oncol 2003, 29(1):81-86.
  194. Audet N, Palme CE, Gullane PJ, Gilbert RW, Brown DH, Irish J, Neligan P: Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome. Head Neck 2004, 26(8):727-732.
  195. Khurana VG, Mentis DH, O"Brien CJ, Hurst TL, Stevens GN, Packham NA: Parotid and neck metastases from cutaneous squamous cell carcinoma of the head and neck. Am J Surg 1995, 170(5):446-450.
  196. O"Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS, Jackson MA: Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck 2002, 24(5):417-422.
  197. Chua MS, Veness MJ, Morgan G, Shakespeare T, Hehir A, Gebski V, Cakir B, Tiver KW: Parotid lymph-node metastases from cutaneous squamous-cell carcinomas: treatment outcome and prognostic factors following surgery and adjuvant radiotherapy. Australas Radiol 2002, 46(2):174-179.
  198. Dona E, Veness MJ, Cakir B, Morgan GJ: Metastatic cutaneous squamous cell carcinoma to the parotid: the role of surgery and adjuvant radiotherapy to achieve best outcome. ANZ J Surg 2003, 73(9):692-696.
  199. Palme CE, O"Brien CJ, Veness MJ, McNeil EB, Bron LP, Morgan GJ: Extent of parotid disease influences outcome in patients with metastatic cutaneous squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2003, 129(7):750-753.
  200. Apisarnthanarax S, Dhruva N, Ardeshirpour F, Tepper JE, Shores CG, Rosenman JG, Shockley WW, Hayward MC, Hayes DN: Concomitant radiotherapy and chemotherapy for high-risk nonmelanoma skin carcinomas of the head and neck. Int J Surg Oncol 2011, 2011:464829.
  201. Kwan W, Wilson D, Moravan V: Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 2004, 60(2):406-411.
  202. Balamucki CJ, Mancuso AA, Amdur RJ, Kirwan JM, Morris CG, Flowers FP, Stoer CB, Cognetta AB, Mendenhall WM: Skin carcinoma of the head and neck with perineural invasion. Am J Otolaryngol 2012, 33(4):447-454.
  203. Maubec E, Helfen S, Scheer-Senyarich I, Boubaya M, Schischmanoff O, Alloux C, Deschamps L, Petrow P, Lopez I, Tibi A et al: CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC). Journal of Clinical Oncology 2017, 35(15_suppl):TPS9596-TPS9596.
  204. Stevenson ML, Wang CQ, Abikhair M, Roudiani N, Felsen D, Krueger JG, Pavlick AC, Carucci JA: Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab. JAMA Dermatol 2017, 153(4):299-303.
  205. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C et al: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016, 17(7):956-965.
  206. Deinlein T, Lax SF, Schwarz T, Giuffrida R, Schmid-Zalaudek K, Zalaudek I: Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature. Eur J Cancer 2017, 83:99-102.
  207. Papadopoulos KP, Johnson ML, Lockhart AC, Moore KN, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ et al: First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low Dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res 2019.
  208. Choi FD, Kraus CN, Elsensohn AN, Carley SK, Lehmer LM, Nguyen RT, Linden KG, Shiu J: Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. J Am Acad Dermatol 2019.
  209. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C et al: Nivolumab vs investigator"s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018, 81:45-51.
  210. Markham A, Duggan S: Cemiplimab: First Global Approval. Drugs 2018, 78(17):1841- 1846.
  211. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS et al: PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 2018, 379(4):341-351.
  212. Sidaway P: Cemiplimab effective in cutaneous SCC. Nat Rev Clin Oncol 2018, 15(8):472.
  213. Ahmed SR, Petersen E, Patel R, Migden MR: Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol 2019, 12(10):947-951.
  214. Ali SA, Arman HE, Patel AA, Birhiray RE: Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation. J Oncol Pract 2019:JOP1900567.
  215. Burova E, Hermann A, Dai J, Ullman E, Halasz G, Potocky T, Hong S, Liu M, Allbritton O, Woodruff A et al: Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther 2019, 18(11):2051-2062.
  216. Hernandez-Guerrero T, Doger B, Moreno V: Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Drugs Today (Barc) 2019, 55(8):485-494.
  217. Vanhakendover L, Lebas E, Libon F, Wauters O, Dezfoulian B, Marchal N, Rorive A, Piret P, Quatresooz P, Jacquemin D et al: [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab]. Rev Med Liege 2019, 74(7-8):436-440.
  218. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C et al: Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016, 375(19):1856-1867.
  219. Modification of the Dosage Regimen for Nivolumab [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm]
  220. Guthrie TH, Porubsky ES: Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis-diamminedichloroplatinum III and doxorubicin. Laryngoscope 1982, 92(11):1298-1299.
  221. Guthrie TH, Jr., McElveen LJ, Porubsky ES, Harmon JD: Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer 1985, 55(8):1629-1632.
  222. Ikegawa S, Saida T, Obayashi H, Sasaki A, Esumi H, Ikeda S, Kiyohara Y, Hayasaka K, Ishihara K: Cisplatin combination chemotherapy in squamous cell carcinoma and adenoid cystic carcinoma of the skin. J Dermatol 1989, 16(3):227-230.
  223. Khansur T, Kennedy A: Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer 1991, 67(8):2030-2032.
  224. Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, Eliachar I, Strome M, Larto MA: Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000, 88(4):876-883.
  225. Goppner D, Nekwasil S, Franke I, Gollnick H, Leverkus M: Successful combination therapy of a locally advanced squamous cell carcinoma of the skin with cetuximab and gamma-irradiation. J Dtsch Dermatol Ges 2010, 8(10):826-828.
  226. DeConti RC: Chemotherapy of squamous cell carcinoma of the skin. Semin Oncol 2012, 39(2):145-149.
  227. Bejar C, Maubec E: Therapy of advanced squamous cell carcinoma of the skin. Curr Treat Options Oncol 2014, 15(2):302-320.
  228. Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quereux G, Dreno B: Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat 2014, 25(5):424- 427.
  229. Conen KL, Fischer N, Hofbauer GF, Shafaeddin-Schreve B, Winterhalder R, Rochlitz C, Zippelius A: Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series. Dermatology 2014, 229(2):97-101.
  230. Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, Thomson D, Zarate D, Simpson F, Porceddu SV: Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol 2014, 25(10):2047-2052.
  231. Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, Rao NG: Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 2015, 37(6):840-845.
  232. Nottage MK, Lin C, Hughes BG, Kenny L, Smith DD, Houston K, Francesconi A: Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head Neck 2017, 39(4):679-683.
  233. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology 2010, 11(1):21-28.
  234. Goldberg H, Tsalik M, Bernstein Z, Haim N: [Cisplatin-based chemotherapy for advanced basal and squamous cell carcinomas]. Harefuah 1994, 127(7-8):217-221, 286.
  235. Petre A, Dalban C, Karabajakian A, Neidhardt EM, Roux PE, Poupart M, Deneuve S, Zrounba P, Fayette J: Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule. Oncotarget 2018, 9(31):22038-22046.
  236. Muzaffar J, Khushalani NI, Russell JS, Parameswaran J, Kirtane K, Iglesia JDL, Slebos R, Chung CH: A phase II study of capecitabine (Cape) or 5-fluorouracil (5-FU) with pegylated interferon alpha-2b (Peg-IFNA-2b) in unresectable/metastatic cutaneous squamous cell carcinoma (CSCC). Journal of Clinical Oncology 2019, 37(15_suppl):e21020-e21020.
  237. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V et al: Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011, 29(25):3419-3426.
  238. Gurney H: How to calculate the dose of chemotherapy. Br J Cancer 2002, 86(8):1297- 1302.
  239. de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJ, Planting AS, Nooter K, Stoter G, Sparreboom A: Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001, 19(17):3733-3739.
  240. Silver JK, Baima J: Cancer prehabilitation: an opportunity to decrease treatment- related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013, 92(8):715-727.
  241. Nilsson H, Angeras U, Bock D, Borjesson M, Onerup A, Fagevik Olsen M, Gellerstedt M, Haglind E, Angenete E: Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. BMJ Open 2016, 6(1):e007997.
  242. Siegel GW, Biermann JS, Chugh R, Jacobson JA, Lucas D, Feng M, Chang AC, Smith SR, Wong SL, Hasen J: The multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework. J Multidiscip Healthc 2015, 8:109-115.
  243. Shehadeh A, El Dahleh M, Salem A, Sarhan Y, Sultan I, Henshaw RM, Aboulafia AJ: Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients" outcome. Hematol Oncol Stem Cell Ther 2013, 6(3-4):105-111.
  244. Cox CL, Montgomery M, Oeffinger KC, Leisenring W, Zeltzer L, Whitton JA, Mertens AC, Hudson MM, Robison LL: Promoting physical activity in childhood cancer survivors: results from the Childhood Cancer Survivor Study. Cancer 2009, 115(3):642-654.
  245. Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI, Committee EG: Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018, 29(Suppl 4):iv166-iv191.
  246. Oren R, Zagury Al, Katzir O, Kollender Y, Meller I: Musculoskeletal Cancer Surgery. In., edn. Edited by Malawer. Dordrecht: Springer; 2013: 583-593.
  247. Committee. NMA: Topic: The Diagnosis and Treatment of Lymphedema. Position Statement of the National Lymphedema Network. . In.; 2011: 1-19.
  248. Segal R, Zwaal C, Green E, Tomasone JR, Loblaw A, Petrella T, Exercise for People with Cancer Guideline Development G: Exercise for people with cancer: a systematic review. Curr Oncol 2017, 24(4):e290-e315.
  249. Boyd C, Crawford C, Paat CF, Price A, Xenakis L, Zhang W, Evidence for Massage Therapy Working G: The Impact of Massage Therapy on Function in Pain Populations-A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part II, Cancer Pain Populations. Pain Med 2016, 17(8):1553-1568.
  250. Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J: A Systematic Review of Exercise Systematic Reviews in the Cancer Literature (2005-2017). PM R 2017, 9(9S2):S347- S384.
  251. Hu M, Lin W: Effects of exercise training on red blood cell production: implications for anemia. Acta Haematol 2012, 127(3):156-164.
  252. Bland KA, Zadravec K, Landry T, Weller S, Meyers L, Campbell KL: Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research. Crit Rev Oncol Hematol 2019, 136:79-85.
  253. Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, Gollhofer A, Bloch W, Baumann FT: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014, 44(9):1289-1304.
  254. Lee JM, Look RM, Turner C, Gardiner SK, Wagie T, Douglas J, Sorenson L, Evans L, Kirchner S, Dashkoff C et al: Low-level laser therapy for chemotherapy-induced peripheral neuropathy. Journal of Clinical Oncology 2012, 30(15_suppl):9019-9019.
  255. Rick O, von Hehn U, Mikus E, Dertinger H, Geiger G: Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2017, 38(2):85-94.
  256. Kilinc M, Livanelioglu A, Yildirim SA, Tan E: Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014, 46(5):454-460.

  1. Oberoi S, Zamperlini-Netto G, Beyene J, Treister NS, Sung L: Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014, 9(9):e107418.
  2. Westphal JG, Schulze PC: Exercise training in cancer related cardiomyopathy. J Thorac Dis 2018, 10(Suppl 35):S4391-S4399.
  3. Ross M, Fischer-Cartlidge E: Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs 2017, 21(2):226-233.
  4. Kessels E, Husson O, van der Feltz-Cornelis CM: The effect of exercise on cancer- related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat 2018, 14:479-494.
  5. Rief H, Omlor G, Akbar M, Welzel T, Bruckner T, Rieken S, Haefner MF, Schlampp I, Gioules A, Habermehl D et al: Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial. BMC Cancer 2014, 14:67.
  6. Bensadoun RJ, Nair RG: Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy. Photomed Laser Surg 2015, 33(10):487-491.
  7. Temoshok L: Biopsychosocial studies on cutaneous malignant melanoma: psychosocial factors associated with prognostic indicators, progression, psychophysiology and tumor-host response. Soc Sci Med 1985, 20(8):833-840.
  8. Dirksen SR: Perceived well-being in malignant melanoma survivors. Oncol Nurs Forum 1989, 16(3):353-358.
  9. Lichtenthal WG, Cruess DG, Schuchter LM, Ming ME: Psychosocial factors related to the correspondence of recipient and provider perceptions of social support among patients diagnosed with or at risk for malignant melanoma. J Health Psychol 2003, 8(6):705-719.
  10. Sollner W, Zschocke I, Zingg-Schir M, Stein B, Rumpold G, Fritsch P, Augustin M: Interactive patterns of social support and individual coping strategies in melanoma patients and their correlations with adjustment to illness. Psychosomatics 1999, 40(3):239- 250.
  11. Devine D, Parker PA, Fouladi RT, Cohen L: The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. Psychooncology 2003, 12(5):453-462.
  12. Folkman S, Lazarus RS, Gruen RJ, DeLongis A: Appraisal, coping, health status, and psychological symptoms. J Pers Soc Psychol 1986, 50(3):571-579.
  13. Беляев АМ, Чулкова ВА, Семиглазова ТЮ, Рогачев МВ (eds.): Онкопсихология для врачей-онкологов и медицинских психологов. Руководство. СПб: Любавич; 2017.
  14. Fawzy FI, Cousins N, Fawzy NW, Kemeny ME, Elashoff R, Morton D: A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance. Arch Gen Psychiatry 1990, 47(8):720-725.
  15. Holland JC, Passik S, Kash KM, Russak SM, Gronert MK, Sison A, Lederberg M, Fox B, Baider L: The role of religious and spiritual beliefs in coping with malignant melanoma. Psychooncology 1999, 8(1):14-26.
  16. Baider L, Perry S, Sison A, Holland J, Uziely B, DeNour AK: The role of psychological variables in a group of melanoma patients. An Israeli sample. Psychosomatics 1997, 38(1):45- 53.
  17. Lehto US, Ojanen M, Kellokumpu-Lehtinen P: Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. Ann Oncol 2005, 16(5):805-816.
  18. Fawzy FI, Fawzy NW, Hyun CS, Elashoff R, Guthrie D, Fahey JL, Morton DL: Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993, 50(9):681-689.
  19. Fawzy FI, Kemeny ME, Fawzy NW, Elashoff R, Morton D, Cousins N, Fahey JL: A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Arch Gen Psychiatry 1990, 47(8):729-735.
  20. Fawzy FI, Canada AL, Fawzy NW: Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch Gen Psychiatry 2003, 60(1):100-103.
  21. Boesen EH, Boesen SH, Frederiksen K, Ross L, Dahlstrom K, Schmidt G, Naested J, Krag C, Johansen C: Survival after a psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 2007, 25(36):5698-5703.
  22. Boesen EH, Ross L, Frederiksen K, Thomsen BL, Dahlstrom K, Schmidt G, Naested J, Krag C, Johansen C: Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 2005, 23(6):1270-1277.
  23. McLoone J, Menzies S, Meiser B, Mann GJ, Kasparian NA: Psycho-educational interventions for melanoma survivors: a systematic review. Psychooncology 2013, 22(7):1444- 1456.
  24. Sample A, He YY: Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 2018, 34(1):13-24.
  25. Craig S, Earnshaw CH, Viros A: Ultraviolet light and melanoma. J Pathol 2018, 244(5):578-585.
  26. Runger TM: Mechanisms of Melanoma Promotion by Ultraviolet Radiation. J Invest Dermatol 2016, 136(9):1751-1752.
  27. Green AC, Williams GM, Logan V, Strutton GM: Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011, 29(3):257-263.
  28. Ghiasvand R, Weiderpass E, Green AC, Lund E, Veierod MB: Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study. J Clin Oncol 2016, 34(33):3976-3983.
  29. Marcil I, Stern RS: Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000, 136(12):1524-1530.
  30. Kiiski V, de Vries E, Flohil SC, Bijl MJ, Hofman A, Stricker BH, Nijsten T: Risk factors for single and multiple basal cell carcinomas. Arch Dermatol 2010, 146(8):848-855.
  31. Sanchez G, Nova J, Rodriguez-Hernandez AE, Medina RD, Solorzano-Restrepo C, Gonzalez J, Olmos M, Godfrey K, Arevalo-Rodriguez I: Sun protection for preventing basal cell and squamous cell skin cancers. Cochrane Database Syst Rev 2016, 7:CD011161.
  32. Badertscher N, Meier M, Rosemann T, Braun R, Cozzio A, Tag B, Wensing M, Tandjung R: The role of skin self-examination at the Swiss skin cancer day. BMC Health Serv Res 2014, 14:581.
  33. Wu S, Han J, Li WQ, Li T, Qureshi AA: Basal-cell carcinoma incidence and associated risk factors in U.S. women and men. Am J Epidemiol 2013, 178(6):890-897.
  34. Karagas MR, Stukel TA, Greenberg ER, Baron JA, Mott LA, Stern RS: Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992, 267(24):3305-3310.
  35. Ramachandran S, Rajaratnam R, Smith AG, Lear JT, Strange RC: Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma. J Am Acad Dermatol 2009, 61(2):247-251.
  36. Flohil SC, Koljenovic S, de Haas ER, Overbeek LI, de Vries E, Nijsten T: Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands. Br J Dermatol 2011, 165(4):874-881.
  37. Flohil SC, van der Leest RJ, Arends LR, de Vries E, Nijsten T: Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer 2013, 49(10):2365-2375.
  38. Aryasit O, Preechawai P, Hajeewaming N: Clinicopathologic Characteristics and Predictors Affecting Survival Outcome of Eyelid Malignancy. J Craniofac Surg 2019, 30(5):1516-1519.
  39. Schneider J: The teaspoon rule of applying sunscreen. Arch Dermatol 2002, 138(6):838-839.
  40. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6):649-655.

Для продолжения работы требуется вход / регистрация